There is no radical cure for patients with advanced disease, and the goal of treatment is to control disease progression and relieve symptoms.
Squamous lung cancer, also known as squamous epithelial cell carcinoma of the lung, is the most common type, accounting for 40% to 51% of primary lung cancers. Squamous lung cancer is mostly seen in older men and is closely related to smoking. Squamous lung cancer is more common in the central type of lung cancer and has the tendency to grow in the chest tube lumen. Early stage of squamous lung cancer often causes bronchial stenosis or obstructive pneumonia. With the advancement of targeted therapy and immunotherapy, there is now a breakthrough in the treatment of advanced lung squamous carcinoma, such as the application of PD-1 combined with chemotherapy in advanced lung squamous carcinoma and the application of PD-1 alone in advanced lung squamous carcinoma, which have given many patients with advanced lung squamous carcinoma hope for long-term survival. Treatment of advanced lung squamous carcinoma is given along with supportive therapy. New chemotherapeutic drugs are also used for patients with advanced stage, which can provide some degree of remission. Therefore, advanced pulmonary squamous carcinoma is not drug-free. With further in-depth exploration of immunotherapy and targeted therapy in pulmonary squamous carcinoma and better human understanding of cancer and immunotherapy, the treatment options for advanced pulmonary squamous carcinoma are gradually increasing and confirmed by clinical practice data. Specific treatment options need to be analyzed based on the overall status of the patient.